Medical Device News Magazine

Assessing the Cardiac Risks of Cobalt in Hip Replacements

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

A technique for measuring the cardiac risk associated with cobalt – containing hip replacements has been highlighted for the first time in research at the University of Strathclyde.

Some hip replacements can contain Cobalt and could potentially affect heart function in some patients. The study has also identified, for the first time, a link between cobalt-induced changes in calcium levels in heart muscle cells and reduced contraction of the heart.

The Strathclyde study, funded by Heart Research UK, aimed to investigate the damaging effects of cobalt on heart cells and tissue. The research team examined a potential relationship between cobalt exposure and changes in the levels and activity of a protein called CaMKII. This protein is known to play a central role in regulating heart function in both health and disease.

The researchers looked at the best way to measure cobalt-induced effects in patients. Global longitudinal strain, a sensitive form of ultrasound, was found to be a good way of measuring which hip replacement patients are most at risk of heart complications. The researchers also measured the impact of cobalt across a range of experimental settings, including its effects on two types of heart cells and on cardiovascular function in both a laboratory model and humans.

The research demonstrated that cobalt, even at low levels, can reduce heart contraction, making the heart less efficient at pumping blood around the body. Calcium plays a key role in regulating heart contraction and it is thought that the effects of cobalt on CaMKII and calcium levels within the heart cells contributes to this reduction in contraction. The results from the study highlight the potential for both early intervention and prevention of damaging effects of cobalt in the heart.

The research team comprised scientists in Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) and the University’s Department of Biomedical Engineering, along with Orthopaedic clinicians at Queen Elizabeth University Hospital.

Dr Susan Currie, a Reader in SIPBS, is leading the research. She said: “Hip replacements are the current treatment for advanced cases of arthritis. However, there is now very strong evidence of a link between hip replacements where metals such as cobalt and chromium are used in the artificial joint bearings, and the possibility of developing heart complications.

“While not all hip replacements contain cobalt, for those that do, cobalt levels can rise over time in the bloodstream of patients and the metal can accumulate in various organs of the body, including the heart. Left untreated, this can damage the heart and, in some cases, lead to heart failure, but doctors cannot tell whether, or when, hip replacement patients will develop heart complications.

“Despite the knowledge that cobalt in some hip replacements has the potential to cause heart complications, our research is the first time a robust way of measuring risk has been found. This is also the first time that a link between cobalt-induced changes in calcium levels in heart muscle cells and reduced contraction of the heart has been identified. Cementing this knowledge will allow further study to focus on new treatments to reduce or prevent the toxic effects of cobalt in patients with hip replacements.

“Our findings confirm a mechanism by which cobalt can negatively impact heart function. This has significant implications in terms of care for people who have received hip replacements which contain cobalt and who therefore may be at increased risk for the development of longer-term cardiac complications.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”